NCT04892459View on ClinicalTrials.gov

Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector)

PHASE4CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

July 25, 2021

Study Completion Date

December 25, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

Recombinant SARS-CoV-2 Ad5 vectored vaccine

This vaccine contains 5×10\^10 virus particles of recombinant replication defective human type 5 adenovirus expressing SARS-CoV-2 S protein, which is produced by CanSino Biologics Inc. It is a liquid dosage form, 0.5 ml / bottle.

BIOLOGICAL

Inactive SARS-CoV-2 vaccine (Vero cell)

This vaccine contains 600 SU of SARS-CoV-2 antigen, which is produced by Sinovac Research \& Development Co., Ltd. 0.5 ml / bottle.

Trial Locations (1)

210009

Jiangsu Provincial Center for Disease Control and Prevention, Nanjing

Sponsors

Collaborators (1)

CanSino Biologics Inc.
All Listed Sponsors
collaborator

CanSino Biologics Inc.

INDUSTRY

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

NCT04892459 - Study on Sequential Immunization of Inactivated SARS-CoV-2 Vaccine and Recombinant SARS-CoV-2 Vaccine (Ad5 Vector) | Biotech Hunter | Biotech Hunter